Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SDCBP | O00560 | 1/20 | 0.38 |
| ▸ | SDC2 | P34741 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452141 | 0.88 | PPARA (0.50) | PPARAPPARG | |
| SCHEMBL5450481 | 0.87 | L3MBTL1 (0.37) | PPARAPPARGL3MBTL1SDCBPSDC2 | |
| SCHEMBL5450485 | 0.84 | ALDH1A1 (0.36) | PPARAPPARGL3MBTL1SDCBPSDC2 | |
| SCHEMBL5450388 | 0.81 | PPARA (0.54) | PPARAPPARG | |
| SCHEMBL5449473 | 0.77 | ALDH1A1 (0.42) | PPARAPPARG | |
| SCHEMBL5449476 | 0.72 | ALDH1A1 (0.40) | PPARAPPARG | |
| SCHEMBL5440986 | 0.71 | PPARA (0.54) | PPARAPPARGL3MBTL1 | |
| SCHEMBL1876957 | 0.70 | PPARA (0.49) | PPARAPPARG | |
| SCHEMBL5797721 | 0.69 | PPARA (0.51) | PPARAPPARG | |
| SCHEMBL5797727 | 0.69 | PPARA (0.51) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | CADILA HEALTHCARE LIMITED (IN) | 2007-05-10 | — | — | US | claimed |
| EP-1709035-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LTD. (IN) | 2006-10-11 | — | — | EP | claimed |
| WO-2005077943-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | claimed |
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | CADILA HEALTHCARE LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| EP-1709035-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LTD. (IN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005077943-A1 | 1 , 3 - DIOXANE DERIVATIVES AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF I.A. OBESITY AND DIABETES | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | GPR119, PPARG, FABP4 | PPARA 4/4885PPARG 2/4885L3MBTL1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.